THC Therapeutics, Inc. (THCT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
THC Therapeutics, Inc. (THCT) trades at $0.0006. THC Therapeutics, Inc. focuses on the wellness industry, developing the dHydronator, a sanitizing herb dryer. The company, formerly Millennium Blockchain, Inc. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for THCT: THCT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates THCT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
THCT: 2/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →THC Therapeutics, Inc. (THCT) Healthcare & Pipeline Overview
THC Therapeutics, Inc., operating in the wellness sector, develops the dHydronator, a sanitizing herb dryer targeting the cannabis, herb, flower, and tea leaf markets. The company faces competition and regulatory hurdles typical of the specialty drug manufacturing and cannabis-adjacent industries.
What Is the Investment Thesis for THCT?
THC Therapeutics, Inc. presents a speculative investment opportunity within the niche market of cannabis and herb processing equipment. The company's focus on the dHydronator, a sanitizing herb dryer, targets a specific need within the cultivation and processing workflow. Growth catalysts include potential partnerships with cannabis cultivators and distributors, as well as expansion into related markets such as herbal medicine and tea production. However, the company's small size, limited operating history, and OTC listing present significant risks. Key value drivers depend on successful product commercialization, market acceptance, and the ability to secure funding for expansion. The company's high beta of 7.53 indicates significant volatility, and its negative P/E ratio of -0.47 reflects current unprofitability.
Based on FMP financials and quantitative analysis
THCT Key Highlights
THC Therapeutics operates in the wellness industry, focusing on equipment for cannabis and herb processing.
- The company's primary product is the dHydronator, a sanitizing herb dryer.
- The company rebranded from Millennium Blockchain, Inc. in September 2018.
- THC Therapeutics is based in Las Vegas, Nevada, and was incorporated in 2007.
- The company has a market capitalization of $0.00B and a P/E ratio of -0.47.
Who Are THCT's Competitors?
THCT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are THCT's Key Strengths?
Specialized product (dHydronator) targeting a niche market.
- Focus on the growing cannabis and wellness industries.
- Potential for innovation in drying and sanitization technologies.
- Adaptability to related markets such as herbal medicine and tea processing.
What Are THCT's Weaknesses?
Small company size with limited resources.
- Limited operating history and market presence.
- Dependence on a single product (dHydronator).
- OTC listing with associated risks.
What Could Drive THCT Stock Higher?
Potential partnerships with cannabis cultivators and distributors.
- Expansion into herbal medicine and tea processing markets.
- Development of advanced drying and sanitization technologies.
- Increasing legalization and commercialization of cannabis in various jurisdictions.
- Growing demand for efficient and hygienic processing methods in the cannabis industry.
What Are the Key Risks for THCT?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Competition from established equipment manufacturers.
- Regulatory changes in the cannabis industry.
- Technological obsolescence.
- Small company size with limited resources.
- OTC listing with associated risks.
What Are the Growth Opportunities for THCT?
- Expansion into the cannabis cultivation market: The increasing legalization of cannabis creates a growing demand for efficient and reliable drying and sanitization equipment. THC Therapeutics can capitalize on this trend by targeting cannabis cultivators with its dHydronator product. The global cannabis market is projected to reach $57 billion by 2027, presenting a substantial opportunity for growth. Success depends on effective marketing, competitive pricing, and establishing distribution channels within the cannabis industry.
- Diversification into herbal medicine and tea processing: The dHydronator's application extends beyond cannabis to include other herbs, flowers, and tea leaves. THC Therapeutics can diversify its revenue streams by targeting the herbal medicine and tea processing industries. The global herbal medicine market is estimated at $83 billion, while the tea market is valued at $20 billion. This expansion requires adapting the dHydronator to meet the specific needs of these industries and establishing partnerships with relevant businesses.
- Development of advanced drying and sanitization technologies: Investing in research and development to create more advanced drying and sanitization technologies can provide a competitive edge. This includes exploring innovations such as AI-powered process optimization, energy-efficient designs, and enhanced sanitization methods. The market for advanced processing equipment is driven by the demand for higher product quality, reduced processing costs, and improved sustainability. Securing patents for new technologies can further strengthen the company's competitive position.
- Strategic partnerships with equipment distributors: Establishing partnerships with established equipment distributors can expand THC Therapeutics' reach and market penetration. Distributors provide access to a wider customer base and established sales channels. This strategy requires identifying suitable distribution partners with relevant industry experience and a strong track record. Effective partnership management and clear communication are essential for success.
- Licensing the dHydronator technology: Licensing the dHydronator technology to other manufacturers can generate revenue and expand the product's availability without requiring significant capital investment. This strategy involves identifying potential licensees, negotiating licensing agreements, and providing technical support. Licensing can be particularly attractive in international markets where THC Therapeutics may lack a direct presence. Careful consideration must be given to protecting intellectual property and ensuring quality control.
What Are THCT's Competitive Advantages?
- Specialized product (dHydronator) addressing a specific need.
- First-mover advantage in the sanitizing herb dryer market.
- Potential for intellectual property protection through patents.
- Focus on a niche market (cannabis and related industries).
What Does THCT Do?
THC Therapeutics, Inc., established in 2007 and based in Las Vegas, Nevada, operates within the wellness industry, focusing on the development of specialized drying and sanitization equipment. Originally incorporated as Millennium Blockchain, Inc., the company rebranded in September 2018 to reflect its strategic shift towards the cannabis and related markets. Its primary product, the dHydronator, is designed to dry and sanitize freshly harvested cannabis, herbs, flowers, and tea leaves, addressing a critical need for efficient and hygienic processing in these sectors. The dHydronator aims to provide a solution for businesses seeking to optimize their drying processes while maintaining product quality and safety. The company's evolution from blockchain technology to wellness solutions highlights its adaptability and focus on emerging market opportunities. As a small company with one employee, THC Therapeutics faces challenges in scaling production and distribution, requiring strategic partnerships and efficient resource management to compete effectively in the market.
What Products and Services Does THCT Offer?
- Develops the dHydronator, a sanitizing herb dryer.
- Targets the cannabis cultivation and processing market.
- Offers a solution for drying and sanitizing freshly harvested cannabis, herbs, flowers, and tea leaves.
- Aims to improve the efficiency and hygiene of the drying process.
- Provides equipment for the wellness industry.
- Focuses on specialized drying and sanitization equipment.
How Does THCT Make Money?
- Sales of the dHydronator to cannabis cultivators and processors.
- Potential revenue from licensing the dHydronator technology.
- Future revenue from maintenance and support services for the dHydronator.
- Expansion into related markets such as herbal medicine and tea processing.
What Industry Does THCT Operate In?
THC Therapeutics, Inc. operates in the evolving landscape of the cannabis and wellness industries. The market for cannabis processing equipment is growing alongside the increasing legalization and commercialization of cannabis in various jurisdictions. This growth is fueled by the demand for efficient and standardized processing methods. The company faces competition from established equipment manufacturers and smaller, specialized firms. Key trends include the adoption of automated systems, the emphasis on product quality and safety, and the increasing focus on sustainable practices. THC Therapeutics aims to carve a niche by offering a sanitizing herb dryer, addressing the specific need for hygienic processing in the cannabis and related sectors.
Who Are THCT's Key Customers?
- Cannabis cultivators.
- Cannabis processors.
- Herbal medicine producers.
- Tea producers.
Financial Health
THC Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for THC Therapeutics, Inc. stands at 12.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
THC Therapeutics, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Jacksboro, US. The company is led by CEO Scott A. Cox. THCT has traded publicly since 2017.
Insider Activity
The most recent 7 insider filings for THC Therapeutics, Inc. break down as 5 sales and 2 purchases. On net that is roughly 7.4M shares disposed (about $192K), a signal worth weighing alongside the fundamentals.
THCT Financials
Bull Case vs Bear Case
Bull Case
- Specialized product (dHydronator) targeting a niche market.
- Focus on the growing cannabis and wellness industries.
- Potential for innovation in drying and sanitization technologies.
- Adaptability to related markets such as herbal medicine and tea processing.
Bear Case
- Small company size with limited resources.
- Limited operating history and market presence.
- Dependence on a single product (dHydronator).
- OTC listing with associated risks.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
THCT Latest News
No recent news available for THCT.
THCT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for THCT.
Price Targets
Wall Street price target analysis for THCT.
THCT MoonshotScore
What does this score mean?
The MoonshotScore rates THCT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Scott A. Cox
CEO
Scott A. Cox serves as the CEO of THC Therapeutics, Inc. Information regarding his detailed professional background and education is not available in the provided data. As CEO, he is responsible for the overall strategic direction and operational management of the company, including the development and commercialization of the dHydronator product. His leadership is critical to the company's success in the competitive cannabis and wellness industries.
Track Record: With limited information available, it is difficult to assess Scott A. Cox's specific track record at THC Therapeutics, Inc. However, the company's rebranding and focus on the dHydronator product suggest a strategic shift under his leadership. The success of the company will depend on his ability to secure funding, establish partnerships, and drive sales of the dHydronator.
THCT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that THC Therapeutics, Inc. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial reports. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and the potential for fraud or manipulation. This contrasts with NYSE/NASDAQ listings, which have stringent financial and governance requirements, offering investors greater transparency and protection.
- OTC Tier: OTC Other
- Limited financial disclosure due to OTC Other status.
- Low liquidity and high bid-ask spreads.
- Potential for price manipulation and fraud.
- Lack of regulatory oversight.
- Higher volatility compared to exchange-listed stocks.
- Verify the company's registration and legal standing.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their experience.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Company's focus on a specific product (dHydronator).
- Operating history since 2007.
- Presence in the growing cannabis and wellness industries.
- Company's efforts to develop and market the dHydronator.
What Investors Ask About THC Therapeutics, Inc. (THCT) — Healthcare
What does THC Therapeutics, Inc. do?
THC Therapeutics, Inc. operates in the wellness industry, focusing on the development and commercialization of the dHydronator, a sanitizing herb dryer. This product is designed for drying and sanitizing freshly harvested cannabis, herbs, flowers, and tea leaves. The company aims to provide a solution for businesses seeking to optimize their drying processes while maintaining product quality and safety.
What do analysts say about THCT stock?
As a thinly traded OTC stock with limited analyst coverage, there is no readily available analyst consensus on THCT. The company's valuation metrics, such as its negative P/E ratio, reflect its current unprofitability. Growth considerations depend on the successful commercialization of the dHydronator and its ability to penetrate the cannabis and related markets.
What are the main risks for THCT?
THC Therapeutics, Inc. faces several significant risks, including its small company size, limited operating history, and OTC listing. The company is dependent on a single product (dHydronator) and faces competition from established equipment manufacturers. Regulatory changes in the cannabis industry could also impact its business.
What are the key factors to evaluate for THCT?
Evaluate THCT on fundamentals, analyst consensus, and risk factors. THC Therapeutics, Inc. presents a speculative investment opportunity within the niche market of cannabis and herb processing equipment. Not financial advice.
How frequently does THCT data refresh on this page?
THCT's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven THCT's recent stock price performance?
THC Therapeutics, Inc. (THCT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized product (dHydronator) targeting a niche market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider THCT overvalued or undervalued right now?
THC Therapeutics, Inc. (THCT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research THCT before investing?
Before investing in THC Therapeutics, Inc. (THCT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC listing carries inherent risks.
- AI analysis pending for THCT.